EP3145935A1 - Composés pharmaceutiquement actifs à titre d'inhibiteurs de lipases dag - Google Patents

Composés pharmaceutiquement actifs à titre d'inhibiteurs de lipases dag

Info

Publication number
EP3145935A1
EP3145935A1 EP16727341.6A EP16727341A EP3145935A1 EP 3145935 A1 EP3145935 A1 EP 3145935A1 EP 16727341 A EP16727341 A EP 16727341A EP 3145935 A1 EP3145935 A1 EP 3145935A1
Authority
EP
European Patent Office
Prior art keywords
pyridin
oxazolo
compound
mmol
tolyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16727341.6A
Other languages
German (de)
English (en)
Inventor
Mario Van Der Stelt
Freek JANSSEN
Marc BAGGELAAR
Jessica HUMMEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Leiden
Original Assignee
Universiteit Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Leiden filed Critical Universiteit Leiden
Publication of EP3145935A1 publication Critical patent/EP3145935A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2

Definitions

  • the present invention relates to novel compounds which are highly selective inhibitors of diacylglycerol lipase-a and - ⁇ . These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by increased 2-arachidonoylglycerol levels.
  • Diacylglycerol lipase-a (alternative name: Sn1 -specific diacylglycerol hydrolase a; DAGL-a or DAGLA) and - ⁇ (alternative name: Sn1 -specific diacylglycerol hydrolase ⁇ ; DAGL- ⁇ or DAGLB) are enzymes responsible for the biosynthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG).
  • inventive and reversible inhibitors are required to study the function of DAGLs in neuronal cells in an acute and temporal fashion.
  • inventive compounds are in particular suitable for the treatment of neurodegenerative diseases, inflammatory diseases, drug abuse and impaired energy balance, such as obesity.
  • Endocannabinoids are endogenous signaling lipids that activate the cannabinoid CBi receptor. They play an essential role in human health and disease, regulating processes, such as immunomodulation, energy balance and neurotransmission. There are two main endocannabinoids: anandamide and 2-arachidonoylglycerol. Both endocannabinoids are often found together, but their levels vary between species, tissue, developmental stage and pathological condition. Selective inhibition of the formation of anandamide and 2-AG would be instrumental to target endocannabinoid specific CB r mediated physiological effects. However, pathway-selective inhibitors for 2-AG and anandamide biosynthesis are currently lacking.
  • 2-AG is mainly formed by the action of two diacylglycerol lipases (DAGL-a and DAGL- ⁇ ).
  • DAGLs are intracellular, multi-domain integral membrane proteins.
  • the DAGLs share extensive homology, but differ in size: -120 and -70 kD for DAGL-a and DAGL- ⁇ respectively.
  • DAGLs belong to the class of serine hydrolases that employ the typical Ser-His-Asp catalytic triad to hydrolyze the ester bond of acyl chains from arachidonate-containing diacylglycerols in a sn-1 specific manner.
  • DAGL knock-out mice Studies with DAGL knock-out mice have shown that DAGL-a controls to a large extent the formation of 2- AG in the central nervous system, whereas DAGL- ⁇ appears to partake in 2-AG production in the periphery during inflammation. Importantly, also basal anandamide levels were reduced in DAGL-a knock-out mice. Selective inhibitors for DAGLs, which can be used in an acute and temporal fashion and do not modulate anandamide levels, would, therefore, constitute an important counterpart of the DAGL knock-out mice, and allow the examination of acute versus congenital inhibition.
  • DAGL inhibitors are based on the natural substrates and/or have reactive chemical warheads, and are not selective over other serine hydrolases that modulate endocannabinoid signaling (e.g. ABHD6, ABHD12, monoacylglycerol lipase (MAGL) or fatty acid amide hydrolase (FAAH)).
  • ABHD6, ABHD12, monoacylglycerol lipase (MAGL) or fatty acid amide hydrolase (FAAH) fatty acid amide hydrolase
  • a-ketoheterocycle 1 -(oxazolo[4,5- b]pyridin-2-yl)-6-phenylhexan-1 -one was identified as the first reversible inhibitor for DAGL-a (Baggelaar et al.; Angew. Chem. Int.
  • ABPP comparative and competitive activity-based proteome profiling
  • broad-spectrum and tailor-made activity-based probes are combined to report on the inhibition of a protein family in its native environment
  • the selectivity of the inhibitors has been shown.
  • Competitive ABPP with broad-spectrum fluorophosphonate-based probes and specific ⁇ -lactone-based probes led to the discovery of the compounds according to the general formula (I) as potent, selective dual DAGL-a/DAGL- ⁇ inhibitors.
  • a-ketoheterocycle of the present invention exhibit particularly high levels of inhibition of the activity of diacylglycerol lipase-a and - ⁇ . Therefore the present invention refers to compounds defined by the general formula (I):
  • X 1 is -CH-, -CF- or -N-;
  • Y represents one of the following moieties:
  • R 1 represents: -CF 3 , -CHF 2 , -CH 2 F, -CF 2 CF 3 , -CHFCF 3 , -CF 2 CHF 2 , -CHFCHF 2 , -CF2CH 2 F, -CHFCH 2 F, -CHFCH 3 , -CF 2 CH 3 , ⁇
  • R 3 and R 4 are independently of each other selected from: -R 8 , -R 9 , -H -OH, -OCH 3 , -OC 2 H 5 , -OC 3 H 7 , -O-cyclo-C 3 H 5 , -OCH(CH 3 ) 2 , -OC(CH 3 ) 3 -OC 4 H 9 , -OPh, -OCH 2 -Ph, -OCPh 3 , -CH2-OCH 3 , -C 2 H 4 -OCH 3 , -C 3 H 6 -OCH 3 — CH;?— OC 2 H5, — C 2 H 4 — OC 2 H5, — C 3 H6— OC 2 Hs, — CH;?— OC 3 H 7 , — C 2 H 4 — OC 3 H 7 -C 3 H 6 -OC 3 H 7 , -CH ⁇ O-cyclo-CsHs, -C 2 H 4 -O-
  • R 5 and R 6 are independently of each other selected from:
  • R 10 represents one of the following groups: -H, -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , — CH2CH2CH3, or — CH2CH2CH2CH3; and enantiomers, stereoisomeric forms, mixtures of enantiomers, diastereomers, mixtures of diastereomers, hydrates, solvates, acid salt forms, tautomers, and racemates of the above mentioned compounds and pharmaceutically acceptable salts thereof.
  • tautomer is defined as an organic compound that is interconvertible by a chemical reaction called tautomerization. Tautomerization can be catalyzed preferably by bases or acids or other suitable compounds.
  • the compounds of the present invention may form salts with organic or inorganic acids or bases.
  • suitable acids for such acid addition salt formation are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, oxalic acid, malonic acid, salicylic acid, p-aminosalicylic acid, malic acid, fumaric acid, succinic acid, ascorbic acid, maleic acid, sulfonic acid, phosphonic acid, perchloric acid, nitric acid, formic acid, propionic acid, gluconic acid, lactic acid, tartaric acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic acid, methanesulfonic acid, ethanesulfonic acid, nitrous acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, p-toluenesul
  • salts could also be formed with inorganic or organic bases.
  • suitable inorganic or organic bases are, for example, NaOH, KOH, NH OH, tetraalkylammonium hydroxide, lysine or arginine and the like.
  • Salts may be prepared in a conventional manner using methods well known in the art, for example by treatment of a solution of the compound of the general formula (I) with a solution of an acid, selected out of the group mentioned above.
  • the fused aromatic system i.e. the oxazolo pyridine system or the oxazolo phenyl system
  • a hydrogen is replaced by another residue other than hydrogen, in particular if the hydrogen is substituted with an aromatic or heteroaromatic ring
  • a substitution of another position at the 6-membered aromatic ring of the fused aromatic system different from the 6-position of the fused aromatic system does not show such an increase of the inhibitory activity against DAGL Consequently, it was found that compounds having a substituent at the 6-position and preferably a cyclic or heterocyclic substituent and more preferably an aromatic or heteroaromatic substituent and still more preferably a 5-membered or 6-membered aromatic or heteroaromatic substituent and especially a 6-membered aromatic or heteroaromatic substituent at 6-position of the fused aromatic system are advantageous over these compounds which do not have such a substituent.
  • X 1 is -CF- or -N-;
  • Y represents one of the following moieties:
  • R 1 represents: -CF 3 , -CHF 2 , -CH 2 F, -CF 2 CF 3 ,
  • R 2 represents one of the following moieties: -CH(CH 3 ) 2 ,
  • R 3 and R 4 are independently of each other selected from: -H, -OCH 3 , -OC2H 5 , -OC3H7, -O-cyclo-C 3 H 5 , -OCH(CH 3 ) 2 , -OC(CH 3 ) 3 , -F, -CI, -Br, -I, -OCF 3 , —
  • R 5 and R 6 are independently of each other selected from:
  • X 1 is -CF- or -N-;
  • Y represents one of the following moieties:
  • R 1 represents: -CF 3 , -CHF 2 , -CH 2 F, -CF 2 CF 3 ,
  • R 2 represents one of the following moieties: -CH( CCHH 33 ))2 2 , -CH(C2H 5 )2,
  • R 3 and R 4 are independently of each other selected from: -H, -OCH 3 , -OC2H 5 , -OC3H7, -O-cyclo-C 3 H 5 , -OCH(CH 3 ) 2 , -OC(CH 3 ) 3 , -F, -CI, -Br, -I, -OCF 3 , — CH2F, — CHF2, — CF 3 , — CF2CF 3 , — CH2CH2F, — CH2CHF2, — CH2CF 3 ,
  • R 5 and R 6 are independently of each other selected from:
  • X 1 represents -N- or -CF-.
  • Another preferred embodiment of the present invention is a compound having the general formula (la),
  • Y represents one of the following moieties:
  • R 1 represents: -CF 3 , -CHF 2 , -CH 2 F, -CF 2 CF 3 , -CHFCF 3 , -CF 2 CHF 2 , -CHFCHF 2 , -CF 2 CH 2 F, -CHFCH 2 F, -CHFCH 3 , -CF 2 CH 3 ,
  • R 2 represents one of the following moieties: -CH(CH 3 ) 2 , -CH 2 CH(CH 3 ) 2 , -C( -CH 2 C(CH 3 ) 3j -CH -CPh 3 , -CH CPh 3 ,
  • R 3 and R 4 are independently of each other selected from: -R 8 , -R 9 , -H -OH, -OCH 3 , -OC 2 H 5 , -OC 3 H 7 , -O-cyclo-C 3 H 5 , -OCH(CH 3 ) 2 , -OC(CH 3 ) 3 -OC 4 H 9 , -OPh, -OCH 2 -Ph, -OCPh 3 , -ChVOCHs, -C 2 H 4 -OCH 3 , -C 3 H 6 -OCH 3 — CH;?— OC 2 H5, — C 2 H 4 — OC 2 H5, — C 3 H6— OC 2 Hs, — CH ⁇ OC 3 H 7 , — C 2 H 4 — OC 3 H 7 -C 3 H 6 -OC 3 H 7 , -CH ⁇ O-cyclo-CsHs, -C 2 H 4 -O-cyclo-C
  • R 7 , R 8 and R 9 are independently of each other selected from:
  • R 10 represents one of the following groups: -H, -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , — CH 2 CH 2 CH3, or — CH 2 CH 2 CH 2 CH3; and enantiomers, stereoisomeric forms, mixtures of enantiomers, diastereomers, mixtures of diastereomers, hydrates, solvates, acid salt forms, tautomers, and racemates of the above mentioned compounds and pharmaceutically acceptable salts thereof.
  • Another more preferred embodiment of the present invention is a compound having the general formula (la),
  • Y represents one of the following moieties:
  • R 2 represents one of the following moieties: -CH(CH 3 ) 2 ,
  • R 3 and R 4 are independently of each other selected from: -H, -OCH 3 , -OC 2 H 5 , -OC 3 H 7 , -O-cyclo-C 3 H 5 , -OCH(CH 3 ) 2 , -OC(CH 3 ) 3 , -F, -CI, -Br, -I, -OCF 3 , — CH 2 F, — CHF 2 , — CF 3 , — CF 2 CF 3 , — CH 2 CH 2 F, — CH 2 CHF 2 , — CH 2 CF 3 ,
  • R 7 is selected from: -H, -F, and -CF 3 ; and enantiomers, stereoisomeric forms, mixtures of enantiomers, diastereomers, mixtures of diastereomers, hydrates, solvates, acid salt forms, tautomers, and racemates of the above mentioned compounds and pharmaceutically acceptable salts thereof.
  • compounds of general formula (I) wherein the linker Y represents -(CH 2 ) n - and wherein n is an integer number from: 1 , 2, 3, 4, 5, 6, 7, 8, 9, and 10,
  • Another embodiment of the invention relates to compounds of the general formula (Va)
  • the invention relates to compounds of the general formula (Vila)
  • the invention refers to compounds of the general formula (Villa)
  • Y is selected from: -CH2-, -C2H 4 - -C3H6-, -C 4 H 8 - -C5H10-, -C6H12-, — C 7 Hi 4 — , - ⁇ — , -CgHi8— , -C10H20— , -CH(CH3)— , -CH(CH3)CH2— , -CH2CH(CH3)— , -CH(CH 3 )-C 2 H 4 -, -CH 2 -CH(CH 3 )CH2-, -CH 2 -CH 2 CH(CH 3 )-, -CH(CH 3 )-C 3 H 6 -,
  • R 3 and R 4 are independently of each other selected from: -R 8 , -R 9 ,
  • R 7 has the meaning as described herein.
  • R 5 and R 6 are independently of each other selected from:
  • R 5 and R 6 are independently of each other selected from:
  • R 5 and R6 independently of each other selected from: -H, -OH, -OCH 3 , -OC 2 H 5 , -OC 3 H 7 , -O-cyclo-C 3 H 5 , -OCH(CH 3 ) 2 , -OC(CH 3 ) 3 , -OC 4 H 9 , -OPh, -OCH2-Ph, -OCPh 3 , -COOCH 3 , -COOC 2 H 5 , -COOC 3 H 7 , -NO 2 , -F, -CI, -Br, -I,
  • R 5 and R 6 independently of each other selected from:
  • a further embodiment of the present invention relates to compounds of the general formula (I)
  • X 1 is -CF- or -N-;
  • Y represents -CH2-, -C2H4-, -C3H6-, -C 4 H 8
  • R 2 represents:
  • R represents -H
  • R 4 represents -H, F
  • R 5 represents -H, -F, -CI, -CH 3 , -C 2 H 5 , -C 3 H 7 , -OCH3, -OC 2 H 5 , -OC 3 H 7 , -COOCH3, -COOC2H5, -COOC 3 H 7 , -CN, -CH 2 F, -CHF 2 , or -CF 3 ;
  • R 6 represents -H, -F, -CI, -CH 3 , -C 2 H 5 , -C 3 H 7 , -OCH 3 , -OC 2 H 5 , -OC 3 H 7 , -COOCHs, -COOC 2 H 5 , -COOC 3 H 7 , -CN, -CH 2 F, -CHF 2 , or -CF 3 ;
  • endocannabinoid signaling pathway the series of molecular signals generated as a consequence of an endocannabinoid binding to a cell surface receptor
  • 2- AG signaling pathway the series of molecular signals generated as a consequence of 2-AG binding to a cell surface receptor.
  • the pathway proceeds with the receptor transmitting the signal to a heterotrimeric G-protein complex and ends with regulation of a downstream cellular process, e.g. transcription.
  • one embodiment of the present invention refers to a compound of general formula (I) for use in the treatment and/or prevention of neurodegenerative diseases, inflammatory disease and impaired energy balance, wherein the compound prevents the formation of prostaglandin ester formation, and in particular prevents formation of prostaglandin E 2 glycerol ester.
  • DAGL-dependent endocannabinoid signalling regulates axonal growth and guidance during development, and is required for the generation and migration of new neurons in the adult brain.
  • Adult neurogenesis constitutes a form of cellular plasticity in the developed brain that impacts on memory, depression and neurodegenerative diseases.
  • diacylglycerol lipase a and diacylglycerol lipase ⁇ can also function independendly of cannabinoid receptors.
  • the product of DAGL, 2-AG is a precursor for synthesis of arachidonic acid and its metabolites (such as prostaglandins).
  • 2-AG is the precursor of arachidonic acid (AA) in a pathway that drives the cyclooxygenase-dependent generation of inflammatory prostaglandins in the brain, which has recently been implicated in the degeneration of dopaminergic neurons in Parkinson's disease.
  • AA arachidonic acid
  • the DAGLs regulate a wide range of biological responses via the generation of a cannabinoid receptor signalling pool of 2-AG, but also serve as 'hub' enzymes in pathways that generate and/or maintain signalling pools of AA and various prostanoids.
  • DAGLs are also key enzymes with regulatory roles in pathological processes, including driving inflammatory responses and neurodegeneration.
  • the compounds of the present invention are efficient inhibitors of DAGLs.
  • inventive compounds are suitable for the use as a pharmaceutically active agent.
  • inventive compounds are suitable for the treatment and/or prevention of DAGL activity induced disorders.
  • one aspect of the present invention refers to the inventive compounds for use in the treatment and/or prevention of neurodegenerative diseases, inflammatory disease and impaired energy balance.
  • the compounds of the invention are capable of inhibiting neurodegeneration and thus, are suitable for the treatment and/or prevention of neurodegenerative diseases, particularly selected from the group comprising or consisting of: amyotrophic lateral sclerosis (ALS), Parkinson's disease, Huntington's disease, spinal muscular-atrophy, progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome), Wilson's disease, multi-system atrophy (MSA-P, MSA-C), Shy-Drager syndrome, Alzheimer's disease, spinocerebellar ataxia (SCA), glaucoma, Pick's disease, Lewy-body disease, Hallervorden-Spatz disease, Creutzfeld-Jakob-disease, Machado-Joseph disease, Friedreich ataxia, non-Friedreich ataxias, Gilles de la Tourette syndrome, familial tremors, olivopontocerebellar degenerations, paraneoplasticcerebral syndromes
  • the compounds of the invention are capable of inhibiting synthesis of 2-AG being a precursor for arachidonic acid and its metabolites, in particular prostaglandin, synthesis and thus, are suitable for the treatment and/or prevention of inflammatory disease in particular of inflammatory disease mediated by arachidonic acid metabolites (such as prostaglandins) or prostaglandin E 2 -glycerol .
  • One preferred embodiment of the present invention refers to the inventive compounds according to general formula (I) for use in the treatment of inflammatory disease caused, induced, initiated and/or enhanced by bacteria, viruses, prions, parasites, fungi, and/or caused by irritative, traumatic, metabolic, allergic, autoimmune, or idiopathic reasons.
  • viruses are selected from the group comprising or consisting of human immunodeficiency virus-l, herpes viruses, herpes simplex virus, herpes zoster virus, humam papiloma virus, influenza virus, rota virus and cytomegalovirus; and the bacteria are selected from the group comprising or consisting of mycoplasma pulmonis, ureaplasma urealyticum, mycoplasma pneumoniae, chlamydia pneumoniae, C. pneumoniae, Escherichia coli, Salmonella, Neisseria meningitidis Staphylococcus aureus, Streptococcal bacteria, Helicobacter pylori, and propriono-bacterium .
  • Another preferred embodiment of the present invention refers to the inventive compounds according to general formula (I) for use in the treatment of inflammatory disease, wherein the inflammatory disease is selected from the group comprising or consisting of inflammatory diseases of the central nervous system (CNS), inflammatory rheumatic diseases, inflammatory diseases of blood vessels, inflammatory diseases of the middle ear, inflammatory bowel diseases, inflammatory diseases of the skin, inflammatory disease uveitis, and inflammatory diseases of the larynx.
  • CNS central nervous system
  • inflammatory rheumatic diseases inflammatory diseases of blood vessels, inflammatory diseases of the middle ear, inflammatory bowel diseases, inflammatory diseases of the skin, inflammatory disease uveitis, and inflammatory diseases of the larynx.
  • prostaglandins play a role in pain.
  • High concentrations of prostaglandins cause pain by direct action upon nerve endings and at low concentrations, they markedly increase sensitivity to pain.
  • Prostaglandins are also incriminated in pain perception within the nervous system. They are produced within the central nervous system and sensitize it to painful substances. Pain is thus induced in two ways (local and central). Therefore one aspect of the present invention refers to the inventive compounds used as analgesic agents.
  • the compounds of the present invention are efficient and highly selective inhibitors of DAGL and have been shown to have an effect on endocannabinoid signaling pathway. Activation of cannabinoid CBi receptors has been implicated in increased food uptake and drug addiction. As a consequence the inventive compounds according to general formula (I) are useful for therapeutic intervention in impaired energy balance and in particular of obesity.
  • Diseases related to impaired energy balance refer to diseases and conditions characterized by pathological disorders of the metabolism mainly caused by deregulated amount of energy eaten and/or metabolized.
  • Energy balance is the relationship between energy intake (food calories taken into the body by food and drink) and energy consumption (calories being used in the body).
  • Energy intake refers to the sum of calories consumed as food and energy expenditure is mainly a sum of internal heat produced and external work.
  • Diseases related to impaired energy balance used herein are particularly, but are not limited to, obesity and diabetes type 2.
  • Obesity is defined as abnormal or excessive fat accumulation that may impair health.
  • the body mass index (BMI; weight in kg divided by height in meters squared) may be used to classify overweight and obesity. BMI are sex and age dependent. In general overweight is defined as having a BMI > 25 kg/m 2 and obesity is defined as having a BMI > 30 kg/m 2 .
  • Another embodiment of the present invention refers to the compounds according to general formula (I) for use in the treatment of drug abuse or drug addiction. It is preferred that the drug is selected from the group comprising or consisting of ⁇ 9 - tetrahydrocannabinol, ethanol, nicotine, cocaine and opiates.
  • compositions comprising at least one compound according to general formula (I) as an active ingredient, together with at least one pharmaceutically acceptable carrier, excipient and/or diluents.
  • the pharmaceutical compositions of the present invention can be prepared in a conventional solid or liquid carrier or diluents and a conventional pharmaceutically-made adjuvant at suitable dosage level in a known way.
  • the preferred preparations are adapted for oral application or parenteral application via injection.
  • administration forms include, for example, pills, tablets, film tablets, coated tablets, capsules, liposomal formulations, micro- and nano-formulations, powders and deposits.
  • compositions according to the present invention containing at least one compound according to the present invention, especially one pure optical isomer, and/or a pharmaceutically acceptable salt thereof as active ingredient will typically be administered together with suitable carrier materials selected with respect to the intended form of administration, i.e. for oral administration in the form of tablets, capsules (either solid filled, semi-solid filled or liquid filled), powders for constitution, aerosol preparations consistent with conventional pharmaceutical practices.
  • suitable carrier materials selected with respect to the intended form of administration, i.e. for oral administration in the form of tablets, capsules (either solid filled, semi-solid filled or liquid filled), powders for constitution, aerosol preparations consistent with conventional pharmaceutical practices.
  • suitable formulations are gels, elixirs, dispersable granules, syrups, suspensions, creams, lotions, solutions, emulsions, suspensions, dispersions, and the like.
  • Suitable dosage forms for sustained release include tablets having layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
  • excipient and/or diluents can be used carriers such as preferably with an inert carrier like lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid filled capsules).
  • an inert carrier like lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid filled capsules).
  • Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes, sugars such as sucrose, starches derived from wheat corn rice and potato, natural gums such as acacia, gelatin and tragacanth, derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate, cellulose materials such as methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethylcellulose, polyvinylpyrrolidone, and inorganic compounds such as magnesium aluminum silicate.
  • Lubricants are selected from the group comprising of comsiting of boric acid, sodium benzoate, sodium acetate, sodium chloride, magnesium stearate, calcium stearate, or potassium stearate, stearic acid, high melting point waxes, and other water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and D,L-leucine.
  • Suitable diluents are water or water/propylene glycol solutions for parenteral injections, juice, sugars such as lactose, sucrose, mannitol, and sorbitol, starches derived from wheat, corn rice, and potato, and celluloses such as microcrystalline cellulose. Description of the Figures
  • Figure 2 shows selectivity of inventive compound 25 (LEI105).
  • (a) Competitive ABPP in the mouse brain membrane proteome with comparative compound 1 (10 ⁇ ), inventive compound 25 (LEI105) (10 ⁇ ), OMDM188 (1 ⁇ ) and THL (1 ⁇ ) using TAMRA-FP (500 nM).
  • DSI is induced with a 5-sec duration depolarization from -80 mV to 0 mV and is observed as a marked and brief reduction of IPSC amplitude following the depolarization
  • (c) Initial DSI amplitude under control conditions (DMSO) and in the presence of LEI105 (10 ⁇ ). (*P ⁇ 0.05) Examples
  • ABP Activity based probe
  • CDI Carbodiimidazole
  • CHOK1 hCBi_bgal CHOK1 cell line expressing human cannabinoid receptor 1
  • CNQX 6-cyano-7-nitroquinoxaline-2,3-dione
  • DPBS Dulbecco's phosphate-buffered saline
  • FAAH Fatty acid amide hydrolase
  • GK Glycerol kinase
  • hDAGL-a Human Sn1 specific diacylglycerol lipase-a
  • hDAGL- ⁇ Human Sn1 specific diacylglycerol lipase- ⁇
  • HEMNB HEPES, EDTA, MgCI 2 , NaCI, BSA
  • IPSC Inhibitory postsynaptic currents
  • LAH Lithium aluminium hydride
  • Na-GTP Guanosine 5'-triphosphate sodium salt hydrate
  • NBS /V-bromosuccinimide NMR: Nuclear magnetic resonanc
  • PBS Phosphate-buffered saline
  • PNP-butyrate Paranitrophenylbutyrate
  • TAMRA Carboxytetramethylrhodamine
  • the biochemical hDAGL-a activity assay is based on the hydrolysis of paranitrophenylbutyrate (PNP-butyrate) by membrane preparations from HEK293T cells transiently transfected with hDAGL-a. 200 ⁇ reactions were performed in flat bottom Greiner 96-wells plates in a 50 mM pH 7.2 Hepes buffer. Membrane protein fractions from HEK293T cells transiently transfected with hDAGL-a (0.05 pg/pL final concentration) were used as hDAGL-a source. Compounds to be tested were introduced in 5 ⁇ DMSO.
  • PNP-butyrate paranitrophenylbutyrate
  • ABPP Activity-based protein profiling
  • ABP activity-based probes
  • An ABP normally consists of a covalent, irreversible enzyme inhibitor featuring a reporter entity (fluorophore, biotin, bioorthogonal tag) to label the active site of the enzyme or enzyme family at hand.
  • ABPP is unique in its ability to rapidly identify inhibitor activity and selectivity within large enzyme families in complex proteome samples.
  • mice brain proteome (2.0 mg/mL, 20 ⁇ _) was preincubated for 30 min with vehicle (DMSO) or compound to be tested in 0.5 ⁇ _ DMSO at rt. And subsequently treated with 500 nM (final concentration) TAMRA-FP (TAMRA-FP was bought at Thermo Fischer) for 15 minutes at rt. The reactions were quenched with 10 ⁇ _ standard 3 SDS page sample buffer. The samples were directly loaded and resolved on SDS page gel (10 % acrylamide). The gels were scanned with a ChemiDoc MP sytem (Biorad, Cy 3 settings, 605/50 filter) and analyzed using Image Lab 4.1 .
  • the percentage effect on FAAH was determined by measuring the integrated optical intensity of the band corresponding to FAAH ( ⁇ 63 kD for mouse) using Image lab software. This activity was corrected for the total protein loading per lane as determined by coomassie staining and imaging with a ChemiDocTM MP sytem (Biorad) followed by determination of the integrated optical intensity per lane by using Image Lab 4.1 software. The intensity of the protein bands from the the samples treated with vehicle was set to 100%.
  • Table 1. shows results of examples 1 and 2.
  • the compound is defined to be active if plC 5 o > 5.0 for hDAGL-a.
  • a compound is selective over FAAH if % Effect (10 ⁇ ) on FAAH ⁇ 50%. N/A means less than 50% probe displacement at 10 ⁇ inhibitor concentration.
  • a pK, of 9.70 was reported for the reference compound 1 .
  • Standard assays were performed in HEMNB buffer (50 mM HEPES pH 7.4, 1 mM EDTA, 5 mM MgCI 2 , 100 mM NaCI, 0.5% (w/v) BSA) in black, flat clear-bottom 96-wells plates (Greiner).
  • Final protein concentration of membrane preparations from DAGL-a- overexpressing HEK293T cells was 50 pg/nriL (10 g per well).
  • Inhibitors were added from 40x concentrated DMSO stocks.
  • a substrate solution of 1 -stearoyl-2-arachidonoyl- sn-glycerol was prepared just prior to use.
  • the SAG stock solution (10 mg/mL in methyl acetate) was dried under argon and subsequently dissolved in 50 mM HEPES buffer (pH 7.0) containing 0.75% (w/v) Triton X-100.
  • the substrate solution was mixed to form an emulsion and stored on ice until use.
  • DAGL-a-overexpressing membranes were incubated with inhibitor for 20 min. Subsequently, assay mix containing glycerol kinase (GK), glycerol-3-phosphate oxidase (GPO), horseradish peroxidase (HRP), adenosine triphosphate (ATP), monoacylglycerol lipase (MAGL), AmplifuTMRed and 1 -stearoyl-2-arachidonoyl-sn- glycerol (SAG) was added and fluorescence was measured in 5 min intervals for 60 min on a GENios microplate reader (Tecan, Giessen, The Netherlands).
  • GK glycerol kinase
  • GPO glycerol-3-phosphate oxidase
  • HRP horseradish peroxidase
  • ATP adenosine triphosphate
  • AML monoacylglycerol lipase
  • Figure 1 C, D In view of the high homology between DAGL-a and DAGL- ⁇ the inventors assesed the activity of compound 25 also on native DAGL- ⁇ . To this end, it was tested whether the ABP probe MB064 was also able to label DAGL- ⁇ .
  • MB064 was incubated with membranes from mock and hDAGL- ⁇ transfected HEK293 cells.
  • MB064 was able to label a protein at the expected molecular weight of DAGL- ⁇ , which was not present in the control membranes, or in S443A-hDAGL ⁇ transfected cells, in which the catalytic serine is replaced by alanine using site-directed mutagenesis ( Figure 1 F).
  • Example 6 Determining proteome-wide selectivity of compound 25 using comparative and competitive chemoproteomics
  • proteome comparative and competitive ABPP was used with a broad-spectrum FP-based probe (TAMRA-FP) and the tailored DAGL-a ABP MB064.
  • TAMRA-FP broad-spectrum FP-based probe
  • DAGL-a ABP MB064 the widely used ⁇ -lactone-based DAGL-inhibitors
  • two broad-spectrum covalent and irreversible serine hydrolase inhibitors were firstly tested.
  • both compounds blocked labeling of at least 4 serine hydrolases at concentrations as low as 1 ⁇ , including ABHD6 and ABHD12, enzymes involved in 2-AG metabolism in the brain ( Figure 2 A,B).
  • Fatty acid amide hydrolase was identified in a previous study as a major off- target for comparative compound 1 .
  • compound 25 did not inhibit labeling of any other band as well, and the inventors conclude that it is highly selective at least within the panel of serine hydrolases targeted by the activity-based probes.
  • the selectivity in brain proteome was examined in a broader and more detailed manner.
  • a semi-quantitative chemoproteomics protocol was adapted, which was previously applied to determine the selectivity profile of the irreversible inhibitor KT-109, using a biotinylated version of MB064 and the FP-probe.
  • Mouse brain proteome 500 ⁇ _, 2.0 mg/mL membrane or soluble fraction was incubated with vehicle (DMSO) or inhibitor (10 ⁇ ) in DMSO for 30 minutes at rt.
  • the proteome was labeled with MB108 (2.5 ⁇ , 30 minutes, rt) or FP-Biotin (5 ⁇ , 30 minutes, 37 °C). Subsequently the labeling reaction was quenched and excess probe was removed by chloroform methanol precipitation.
  • Precipitated proteome was suspended in 500 ⁇ _ 6M Urea/25 mM ammonium bicarbonate and allowed to incubate for 15 minutes. 5 ⁇ _ (1 M DTT) was added and the mixture was heated to 65 °C for 15 minutes.
  • the sample was allowed to cool to rt before 40 ⁇ _ (0.5 M) iodoacetamide was added and the sample was alkylated for 30 minutes in the dark. 140 ⁇ _ 10% (wt/vol) SDS was added and the proteome was heated for 5 minutes at 65 °C.
  • the sample was diluted with 6 ml_ PBS. 100 ⁇ _ of 50% slurry of Avidin-Agarose from egg white (Sigma- Aldrich) was washed with PBS and added to the proteome sample. The beads were incubated with the proteome > 2h. The beads were isolated by centrifugation and washed with 0.5% (wt/vol) SDS and PBS (3x).
  • the proteins were digested overnight with sequencing grade trypsin (promega) in 100 ⁇ _ Pd buffer (100 mM Tris, 100 mM NaCI, 1 mM CaCI 2 , 2 % acetonitrile (ACN) and 500 ng trypsin) at 37 °C with vigorous shaking. The pH was adjusted with formic acid to pH 3 and the beads were removed. The peptides were isotopically labeled by on stage tip dimethyl labeling.
  • stage tips were made by inserting Cis material in a 200 ⁇ _ pipet.
  • the stepwise procedure given in the table below was followed for stage tip desalting and dimethyl labeling.
  • the solutions were eluted by centrifugal force and the constitutions of the reagents are given below.
  • Table 2 shows conditions used for isotopically labelling of peptides
  • Stage tip solution B (100 ⁇ _) 2.5 min 800g
  • Stage tip solution A Stage tip solution A is 0.5% (vol/vol) formic acid (FA) in H 2 O. (Freshly prepared solution)
  • Stage tip solution B Stage tip solution B is 0.5% (vol/vol) FA in 80% (vol/vol)
  • CD 2 0 (Medium) 50 ⁇ NaBH 3 CN (0.6 M) 0.03 M 50 ⁇ .
  • Tryptic peptides were analyzed on a Surveyor nanoLC system (Thermo) hyphenated to a LTQ-Orbitrap mass spectrometer (Thermo).
  • MS/MS For each data-dependent cycle, one full MS scan (300- 2000 m/z) acquired at high mass resolution (60,000 at 400 m/z, AGC target 1 x 106, maximum injection time 1000 ms) in the Orbitrap was followed by three MS/MS fragmentations in the LTQ linear ion trap (AGC target 5 x 103, maximum injection time 120 ms) from the three most abundant ions.
  • Fragmented precursor ions that were measured twice within 10 s were dynamically excluded for 60 s and ions with z ⁇ 2 or unassigned were not analyzed. Subsequent data analysis was performed using maxquant software. Acetylation (protein N term) and Oxidation (M) were set as variable modifications. The false discovery rate was set at 1 % and the peptides were screened against mouse proteome (Uniprot). Serine hydrolases that were identified in at least two repetitive experiments and for which at least 2 unique peptides were identified were considered as valid quantifiable hits.
  • CHOK1 hCBi_bgal cells (CHOK1 cell line expressing human cannabinoid receptor 1 ) were cultured in Ham's F12 Nutrient Mixture supplemented with 10% fetal calf serum, 1 mM glutamine, 50 U/mL penicillin, 50 g/ml streptomycin, 300 mg/mL hygromycin and 800 g/mL geneticin in a humidified atmosphere at 37°C and 5% CO 2 . Cells were subcultured twice a week at a ratio of 1 :20 on 10-cm 0 plates by trypsinization. For membrane preparation the cells were subcultured 1 :10 and transferred to large 15-cm diameter plates.
  • the cells on thirty 15-cm 0 plates were detached from the bottom by scraping them into 5 ml_ phosphate-buffered saline (PBS), collected in 12 ml_ Falcon tubes and centrifuged for 5 minutes at 200 x g (3,000 rpm). The pellets were resuspended in ice- cold 50 mM Tris-HCI buffer and 5 mM MgCI 2 (pH 7.4). An Ultra Thurrax homogenizer (Heidolph Instrucments, Schwabach, Germany) was used to homogenize the cell suspension.
  • PBS phosphate-buffered saline
  • the membranes and the cytosolic fractions were separated by centrifugation at 100,000 x g (31 ,000 rpm) in a Beckman Optima LE-80 K ultracentrifuge (Beckman Coulter Inc., Fullerton, CA) at 4°C for 20 minutes. The pellet was resuspended in 10 mL of Tris-HCI buffer and 5 mM MgC ⁇ (pH 7.4) and the homogenization and centrifugation steps were repeated. Finally, the membrane pellet was resuspended in 10 mL 50 mM Tris-HCL buffer and 5 mM MgC (pH 7.4) and aliquots of 250 ⁇ _ were stored at -80°C. Membrane protein concentrations were measured using the BCA method.
  • [ 3 H]CP55940 displacement assays were used for high throughput screening of cold ligands and the determination of their affinity (K,) and IC 5 o values.
  • Membrane aliquots containing 5 g (CHOK1 hCBi_bgal) of membrane protein were incubated in a total volume of 100 ⁇ _ of assay buffer (50 mM Tris-HCI buffer (pH 7.4), 5 mM MgCI 2 and 0.1 % BSA) at 30 °C for 1 hour, in presence of 3.5 nM [ 3 H]CP55940 (CHOK1 hCBi_bgal). Different concentrations of competing ligand were used for determination of affinity (K,) and IC 5 o values.
  • Nonspecific binding was determined in the presence of 10 ⁇ AM630 (6-lodopravadoline; a selective inverse agonist for the cannabinoid receptor CB2). Incubations were terminated by rapid vacuum filtration to separate the bound and free radioligand through Whatman GF/C filters (Whatman International, Maidstone, UK), precoated with 0.25% (v/v) polyethylenimine, using a Brandel Harvester (Brandel, Gaithersburg, MD). Filters were subsequently washed three times with ice-cold assay buffer and 3.5 mL of the Emulsifier Safe scintillation fluid (Perkin Elmer, Groningen, The Netherlands) was added to each filter. After 2 hours, the filter-bound radioactivity was determined by scintillation spectrometry using a Tri-Carb 2900 TR liquid scintillation counter (Perkin Elmer, Boston, MA).
  • MAGL assay was performed as described below. Standard assays were performed under similar conditions as for the glycerol detection besed DAGL-a activity assay , but at a final protein concentration of 1 .5 g/mL (0.3 g MAGL-overexpressing membranes per well) and with 2-arachidonoylglycerol (2-AG) as the substrate. 2-AG was directly added from a stock solution in acetonitrile and no Triton X-100 was added. Fluorescence was measured in 5 min intervals for 60 min.
  • inventive compounds are highly selective DAGL-inhibitor.
  • inventive compound 25 To test the cellular activity of inventive compound 25, the inventor used Neuro2A cells, which is a mouse neuroblastoma cell line known to express both DAGL-a and DAGL- ⁇ . In a targeted lipidomics experiment the effect of inventive compound 25 on the cellular levels of 2-AG and anandamide was determined. Lipid analysis Neuro2A cells.
  • Neuro2A cells were cultured as described above. Before inhibitor treatment, the culture medium was removed and the cells were washed with warm (37 °C) serum free medium (3x). The cells were treated with vehicle (DMSO) or inhibitor for 1 h at 37 °C in serum free medium. After 1 h of incubation medium was removed and the cells were washed with cold (4°C) PBS (3x) and subsequently suspended in PBS and pelleted. The PBS was removed and the cell pellet was flash frozen and and stored at -80 0 until endocannabinoid extraction.
  • DMSO vehicle
  • PBS cold (4°C) PBS
  • Endocannabinoids were measured using a chip-based nano liquid chromatography (LC) system coupled to a triple quadrupole mass spectrometer.
  • the HPLC-Chip is inserted into the HPLC-Chip-MS interface, which mounts directly on the MS source. It includes a miniature camera for spray visualization, the loading mechanism for chip positioning, the microvalve for flow switching, and fluid connection ports for the nano- LC and microwell- plate autosampler.
  • Chromatographic conditions were achieved on a 1 100 series LC-chip system (Agilent technologies, Walbron, Germany) consisting of a nanoflow pump, a capillary pump, a micro well plate auto sampler with thermostat and a LC-Chip/MS interface (chipcube).
  • the chromatographic separations were performed on an ultra high capacity chip including a 360 nl_ enrichment column and a 150 mm ⁇ 75 ⁇ analytical column, both packed with a Polaris-HR-chip 3 ⁇ C18 phase (Agilent Technologies).
  • the mobile phase was composed of 10mM formic acid/Water (A) and ACN (B).
  • the analytical gradient was performed in two steps: first, the 8ul sample was loaded on the enrichment column during an isocratic enrichment phase using the capillary pump delivering a mobile phase in isocratic mode composed of 40% B at a flow rate of 2 ⁇ _/ ⁇ .
  • the column was flushed with two wash cycles for 8min at 100%B to remove unretained components.
  • a gradient starts at 45%B that linearly increases up to 80% B in 12min at a flow rate of 400nL/min.
  • the column was then rinsed with 95%B for 2 minutes before returning to 45% B.
  • the column was re- equilibrated for 5min prior to the next injection.
  • the total analysis time was 20min for each run.
  • the needle was washed with ACN/H2O (1 /1 , v/v) commanded by an injection program.
  • a 6440 Triple quadrupole equipped with a nonoESI source operating in positive mode was used for MS detection. Capillary voltage was set to 1800V. The drying gas was set at a flow rate of 4L/min and the source temperature was maintained at 365C. Quantification was obtained using static MRM (multiple reaction monitoring) mode of the transistions at m/z 379.3 ⁇ 287.2 for 2 AG, 348.3 ⁇ 62.2 for AEA and 387.3 ⁇ 294.2 for 2AGd8, 356.3 ⁇ 62.2 for AEAd8 (internal standards).
  • Mass hunter workstation (Agilent technologies) was used for instrument control . Raw MS data were processes using mass hunter quantitative analysis work station (Agilent technologies). AEA and 2AG was quantified by using a matrix matched internal standard calibration curve. A concentration-dependent reduction of 2-AG was found in Neuro2A cells, whereas anandamide levels were unaffected (Figure 3C, D).
  • PC3 cells prostate cancer cell line
  • the protocol for lipodomics in PC3 cells is given below.
  • the culture medium was removed and the cells were washed with warm (37 °C) serum free medium (3x).
  • the cells were treated with vehicle (DMSO) or inhibitor for 4h at 37 °C in serum free medium.
  • After 4h of incubation medium was removed and the cells were washed with cold (4°C) DPBS (3x) and subsequently suspended in DPBS and pelleted.
  • the cell pellet metabolome was extracted and by MeOH/CHCl3 extraction and analysed by LCMS/MS of a triple quad mass spectometer (agilent).
  • the concentration of the lipids was determined by comparison with spiked deuterated standards of the lipd species.
  • Inventive compound 25 reduced 2-AG levels, but no change in substrate levels of DAGL was detected, which may suggest that DAG species are rapidly converted into other membrane constituents, such as phosphatidic acid by DAG-kinases.
  • arachidonic acid levels were reduced by inventive compound 25 treatment of PC3 cells. This may indicate that downstream metabolic pathways of 2-AG signaling are also affected and that the biosynthesis of 2-AG is the rate-limiting step. This is in line with a previously reported reduction of arachidonic acid levels in DAGL-a knock-out mice and by KT-109 in mouse liver.
  • Example 8 Reduction of synaptic transmission in hippocampus
  • the cannabinoid CBi receptor-dependent synaptic plasticity was investigated with the inventive compound being highly selective, reversible DAGL inhibitor.
  • Horizontal slices (300 ⁇ ) of the hippocampus were obtained from male C57BL/6 mice (Harlan, the Netherlands) aged 14-19 days postnatal. Experiments were approved by the animal welfare committee of the University of Amsterdam.
  • IPSCs were evoked with 5 sec intervals during a 2-min baseline period, prior to the stimulus evoking depolarization-induced suppression of inhibition (DSI).
  • the maximum amplitude of each IPSC was determined and the mean value of the IPCS amplitudes over this period was calculated and used to normalize the evoked synaptic response.
  • DSI was induced by depolarizing the neuron from -80 to 0 mV for 5 sec.
  • the compounds of the invention can be synthesized according to the general scheme 1 , as previously published (Baggelaar, M. P. et al. Angew. Chem. Int. Ed. 2013, 52, 12081-12085.).
  • Alcohol A can be oxidized (i) and subsequently nitrilated (ii) to cyanohydrin B.
  • cyanohydrin B Upon Pinner reaction (iii), the corresponding imidate (Pinner salt) can be cyclized to the required oxazole containing heterocycle using aminoalcohol C (iv).
  • DMP oxidation (v) provides the active a-keto heterocycle D.
  • Reagents and conditions i) BnBr, Cs 2 CO 3 , DMF, rt, 24 h, 47% ii) NBS, ACN, 0 °C, 15 min, 40%; iii) p-tolylboronic acid, Pd(dppf)CI 2 , Na 2 CO 3 , 7:0.5 DME/H 2 O, reflux, 24h, 90%; iv) 10% Pd/C, H 2 , MeOH, rt, 18 h, 40 v) 1.
  • Reagents and conditions i) 1: AcCI, 1:1 CHC dry EtOH, 0 °C, 2.5 h, 2: 2-Amino-5- bromo-3-fluorophenol, dry EtOH, reflux, 16 h, 40% (2 steps); ii) DMP, dry DCM, rt, 1.5 h, 84%. Hi) Corresponding boronic acid, Pd(PPh 3 ) 4 , CsF, DME, H 2 0, 85 °C, 29-84%. cheme 4: Synthesis compounds 27-29.
  • the crude mixture was coevaporated with toluene (3x5 mL) untill the white solid imidate was obtained.
  • the solid was dissolved in dry EtOH (1 .0 mL) and was added under argon to a sealed and dried microwave tube containing a prestirred solution (80 ° C for 30 minutes, then to rt) of commercially available 2-amino-3-hydroxypyridine (68.8 mg, 0.63 mmol) with pyridine (50 ⁇ , 0.63 mmol) in dry EtOH (4.0 mL).
  • the reaction mixture was heated to reflux (80 ° C) for 8 h.
  • the title compound was synthesized from 2-hydroxy-7-phenylheptanenitrile (1a, 16 mg, 0.57 mmol) and 2-amino-5-(p-tolyl)pyridin-3-ol (77 mg, 0.38 mmol) according to the procedures described for compound 1 a. This yielded 1 -(6-(p-tolyl)oxazolo[4,5-i ]pyridin- 2-yl)-6-phenyl-hexan-1 -ol (32 mg, 0.082 mmol, 22 %) as a brown solid.
  • Dess-Martin periodinane 35 mg, 0.075 mmol was added to a solution of 25a (21 mg, 0.05 mmol) in CH2CI2 (2 ml_) and the reaction mixture was stirred under argon atmosphere overnight. The reaction mixture was quenched with saturated NaHCO3 (aq). The layers were separated and the organic layer was extracted with CH2CI2. The combined organic layers were washed with brine, dried on MgSO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash chromatography over silica gel using toluene/ethyl acetate (90:10) with 1 % Et 3 N.
  • n-BuLi (30.6 ml, 76 mmol) was added dropwise over 10 minutes to a cooled solution (-80 °C) of methyl 2-(dimethoxyphosphoryl)acetate (1 1 .04 mL, 76 mmol) in THF (100 mL) and the resulting mixture was stirred for 1 h. Then 2-phenoxybenzaldehyde (26a, 7.57 g, 38.2 mmol) was added, the reaction mixture was slowly warmed up to rt and stirred overnight. Upon completion the mixture was concentrated in vacuo, saturated NaHCO3 (80 mL) was added and product was extracted using EtOAc (3 x 50 mL).
  • 1-(4-fluoro-6-(4-fluorophenyl)benzo[d ⁇ oxazol-2-yl)-6-phenylhexan-1-one 1 -(6- bromo-4-fluorobenzo-2-oxazolyl)-6-phenylhexan-1 -one (1 eq., 33 mg, 0.085 mmol), 4- fluorophenylboronic acid (5 eq., 59.2 mg, 0.42 mmol), Pd(PPh 3 ) (9.8 mg, 10 mol%), and CsF (8 eq., 102.8 mg, 0.68 mmol) were used as starting substances.
  • 1-(4-fluoro-6-(p-tolyl)benzo[d ⁇ oxazol-2-yl)-6-phenylhexan-1-one 1 -(6-bromo-4- fluorobenzo-2-oxazolyl)-6-phenylhexan-1 -one (1 eq., 33.5 mg, 0.086 mmol), 4- tolylboronic acid (4 eq., 46.7 mg, 0.34 mmol), Pd(PPh 3 ) (9.9 mg, 10 mol%), and CsF (8 eq., 104.4 mg, 8 mmol) were used as starting substances.
  • 1-(4-fluoro-6-(o-tolyl)benzo[d ⁇ oxazol-2-yl)-6-phenylhexan-1-one 1 -(6-bromo-4- fluorobenzo-2-oxazolyl)-6-phenylhexan-1 -one (1 eq., 34.2 mg, 0.088 mmol), 2- tolylboronic acid (4 eq., 47.7 mg, 0.35 mmol), Pd(PPh 3 ) (10.1 mg, 10 mol%), and CsF (8 eq., 106.5 mg, 8 mmol) were used as starting substances.
  • the title compound was synthesized from 2-hydroxy-3-phenylpropanenitrile (34a, 1 12 mg, 0.76 mmol) and 2-amino-5-(p-tolyl)pyridin-3-ol (93 mg, 0.46 mmol) according to procedures described for compound 1 a. This yielded 2-phenyl-1 -(6-(p- tolyl)oxazolo[4,5-i ]pyridin-2-yl)ethan-1 -ol (29 mg, 0.087 mmol, 19%).
  • the title compound was synthesized from 2-hydroxy-4-phenylbutanenitrile (35a, 1 14 mg, 0.71 mmol) and 2-amino-5-(p-tolyl)pyridin-3-ol ( 84 mg, 0.42 mmol) according to procedures described for compound 1a. This yielded 3-phenyl-1 -(6-(p-tolyl)oxazolo[4,5- 6]pyridin-2-yl)propan-1 -ol (24 mg, 0.071 mmol, 17%).
  • the title compound was synthesized from 2-hydroxy-5-phenylpentanenitrile (36a, 108 mg, 0.62 mmol) and 2-amino-5-(p-tolyl)pyridin-3-ol (87 mg, 0.44 mmol) according to procedures described for compound 1 a. This yielded 4-phenyl-1 -(6-(p-tolyl)oxazolo[4,5- 6]pyridin-2-yl)butan-1 -ol (20 mg, 0.056 mmol, 13%).
  • the title compound was synthesized from 1 -(6-(2-chlorophenyl)oxazolo[4,5-i ]pyridin-2- yl)-6-phenylhexan-1 -ol according to the procedures described for compound 1 . This yielded 1 -(6-(2-chlorophenyl)oxazolo[4,5-i ]pyridin-2-yl)-6-phenylhexan-1 -one.
  • 2-amino-5-(4-methoxyphenyl)pyridin-3-ol (41a): The title compound was synthesized from 2-amino-5-bromopyridin-3-ol (300 mg, 1 .08 mmol) and 4- methoxyphenylboronic acid (198 mg, 1 .3 mmol) according to the procedures described for compound 54a This yielded 2-amino-5-(4-methoxyphenyl)pyridin-3-ol (148 mg, 0.69 mmol, 63%).
  • the title compound was synthesized from 5,5,5-trifluoro-2-hydroxypentanenitrile (42a, 1 17 mg, 0,76 mmol) and 2-amino-5-(p-tolyl)pyridin-3-ol (85 mg, 0.42 mmol) according to procedures described for compound 1a. This yielded 4,4,4-trifluoro-1 -(6-(p- tolyl)oxazolo[4,5-i ]pyridin-2-yl)butan-1 -ol (6 mg, 0.017 mmol, 4 %).
  • the title compound was synthesized from 5-(4-fluorophenoxy)-1 -(6-(o-tolyl)oxazolo[4,5- jfc)]pyridin-2-yl)pentan-1 -ol according to the procedures described for compound 1 . This yielded 5-(4-fluorophenoxy)-1 -(6-(o-tolyl)oxazolo[4,5-i ]pyridin-2-yl)pentan-1 -one.
  • 2-amino-5-(3-fluorophenyl)pyridin-3-ol 52a: The title compound was synthesized from 2-amino-5-bromopyridin-3-ol (300 mg, 1.08 mmol) and 3-fluorophenylboronic acid (179 mg, 1.3 mmol) according to the procedures described for compound 54a This yielded 2-amino-5-(3-fluorophenyl)pyridin-3-ol (120 mg, 0.59 mmol, 54%).
  • 6-phenyl-1 -(6-(o-tolyl)oxazolo[4,5-b]pyridin-2-yl)hexan-1 -ol) (54b): Compound 54a (70 mg, 0.35 mmol) was dissolved in EtOH (4 mL), Pyridine (28 ⁇ ,0.35 mmol) was added and the mixture was heated for 15 min to 85 °C. Imidate (as obtained through procedures described for compound 1 a, 174 mg, 0.70 mmol) was dissolved in EtOH (1 .0 mL), added to the reaction mixture and heated to 85 °C for 12 h.
  • 6-phenyl-1 -(6-(o-tolyl)oxazolo[4,5-b]pyridin-2-yl)hexan-1 -one (54): To a solution of 54b (15 mg, 0.04 mmol) in CH2CI2 (2 ml_) was added Dess-Martin periodinane (25 mg, 0.06 mmol) and the reaction mixture was stirred under argon atmosphere overnight. The reaction mixture was quenched with saturated NaHCO3 (aq). The layers were separated and the organic layer was extracted with CH2CI2. The combined organic layers were washed with brine, dried on MgSO 4 , filtered and concentrated under reduced pressure.
  • 2-amino-5-(m-tolyl)pyridin-3-ol (55a): The title compound was synthesized from 2- amino-5-bromopyridin-3-ol (418 mg, 1 .5 mmol) and m-tolyl boron ic acid (300 mg, 2.2 mmol) according to the procedures described for compound 54a This yielded 2-amino- 5-(m-tolyl)pyridin-3-ol (220 mg, 1 .1 mmol, 73%).
  • 6-phenyl-1-(6-(m-tolyl)oxazolo[4,5-b]pyridin-2-yl)hexan-1-one The title compound was synthesized from 55b (60 mg, 0.16 mmol) according to the procedure described for 54. This yielded 6-phenyl-1-(6-(m-tolyl)oxazolo[4,5-b]pyridin-2-yl)hexan- 1-one (45 mg, 0.12 mmol, 76%).
  • 2-amino-5-(2-fluorophenyl)pyridin-3-ol (57a): The title compound was synthesized from 2-amino-5-bromopyridin-3-ol (509 mg, 1 .9 mmol) and 2-flourophenylboronic acid (400 mg, 2.8 mmol) according to the procedures described for compound 54a This yielded 2-amino-5-(2-fluorophenyl)pyridin-3-ol (70 mg, 0.34 mmol, 18%).
  • 2-amino-5-(4-fluorophenyl)pyridin-3-ol (58a): The title compound was synthesized from 2-amino-5-bromopyridin-3-ol (300 mg, 1 .08 mmol) and 4-fluorophenylboronic acid (180 mg, 1 .3 mmol) according to the procedures described for compound 54a This yielded 2-amino-5-(4-fluorophenyl)pyridin-3-ol (100 mg, 0.5 mmol, 50%).
  • Methyl 4-(6-amino-5-hydroxypyridin-3-yl)benzoate (59a): The title compound was synthesized from 2-amino-5-bromopyridin-3-ol (300 mg, 1 .08 mmol) and 4- methoxycarbonylphenylboronic acid (234 mg, 1 .3 mmol) according to the procedures described for compound 54a This yielded methyl 4-(6-amino-5-hydroxypyridin-3- yl)benzoate (150 mg, 0.61 mmol, 57%).
  • 2-amino-5-phenylpyridin-3-ol (62a): The title compound was synthesized from 2-amino-5- bromopyridin-3-ol (500 mg, 1 .8 mmol) and phenylboronic acid (262 mg, 2.2 mmol) according to the procedures described for compound 54a This yielded 2-amino-5-phenylpyridin-3-ol (200 mg, 1 .1 mmol, 61 %).
  • 6-phenyl-1 -(6-phenyloxazolo[4,5-b]pyridin-2-yl)hexan-1 -one (62): The title compound was synthesized from 62b (35 mg, 0.094 mmol) according to the procedure described for 54.
  • 2-amino-5-(3-methoxyphenyl)pyridin-3-ol (63): The title compound was synthesized from 2-amino-5-bromopyridin-3-ol (367 mg, 1 .3 mmol) and 3-methoxyphenylboronic acid (237 mg, 1 .6 mmol) according to the procedures described for compound 54a This yielded 2-amino-5-(3-methoxyphenyl)pyridin-3-ol (80 mg, 0.37 mmol, 28%).
  • 2-(6-amino-5-hydroxypyridin-3-yl)benzonitrile (64a) The title compound was synthesized from 2-amino-5-bromopyridin-3-ol (380 mg, 1 .4 mmol) and 2- cyanophenylboronic acid (300 mg, 2.0 mmol) according to the procedures described for compound 54a This yielded 2-(6-amino-5-hydroxypyridin-3-yl)benzonitrile (90 mg, 0.42 mmol, 30%).
  • 3-(6-amino-5-hydroxypyridin-3-yl)benzonitrile (65a) The title compound was synthesized from 2-amino-5-bromopyridin-3-ol (347 mg, 1.24 mmol) and 3- cyanophenylboronic acid (181 mg, 1.24 mmol) according to the procedures described for compound 54a This yielded 3-(6-amino-5-hydroxypyridin-3-yl)benzonitrile (82 mg, 0.39 mmol, 31%).
  • the title compound was synthesized from 2-hydroxy-6-phenylhexanenitrile (68a, 88 mg, 0.47 mmol) and 2-amino-5-(p-tolyl)pyridin-3-ol (62 mg, 0.31 mmol) according to procedures described for compound 1a. This yielded 5-phenyl-1 -(6-(p-tolyl)oxazolo[4,5- 6]pyridin-2-yl)pentan-1 -ol (21 mg, 0.056 mmol, 18 %).
  • the title compound was synthesized from 1 -(6-(4-chloro-2-methoxyphenyl)oxazolo[4,5- jfc)]pyridin-2-yl)-4,4,4-trifluorobutan-1 -ol (71 b, 27 mg, 0.07 mmol) according to procedures described for compound 1 . This yielded 1 -(6-(4-chloro-2- methoxyphenyl)oxazolo[4,5-i ]pyridin-2-yl)-4,4,4-trifluorobutan-1 -one (22 mg, 0.06 mmol, 82%).
  • the title compound was synthesized from 1 -(6-(benzo[c/][1 ,3]dioxol-5-yl)oxazolo[4,5- b]pyridin-2-yl)-4,4,4-trifluorobutan-1 -ol (73b, 14 mg, 0.038 mmol) according to procedures described for compound 1 . This yielded 1 -(6-(benzo[c ][1 ,3]dioxol-5- yl)oxazolo[4,5-i ]pyridin-2-yl)-4,4,4-trifluorobutan-1 -one (4 mg, 0.01 mmol, 29%).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés qui sont des inhibiteurs sélectifs de la diacylglycérol lipase alpha et bêta. Ces composés peuvent être utilisés pour traiter ou prévenir les troubles associés à, accompagnés ou provoqués par des niveaux de 2-arachidonoylglycérol en hausse. Les diacylglycérol lipases-α (nom alternatif : diacylglycérol hydrolases α spécifiques de Snl; DAGL-α) et -β sont les enzymes responsables de la biosynthèse de l'endocannabinoïde 2-arachidonoylglycérol. Des inhibiteurs sélectifs et réversibles sont requis pour étudier de manière pointue et temporelle la fonction des DAGL dans les cellules neuronales. Les composés selon l'invention se prêtent particulièrement bien au traitement des maladies neurodégénératives, des maladies inflammatoires, de la toxicomanie et d'une altération de l'équilibre énergétique, telle que l'obésité, où X1 est -CH-, -CF- ou -N-.
EP16727341.6A 2015-05-22 2016-05-23 Composés pharmaceutiquement actifs à titre d'inhibiteurs de lipases dag Withdrawn EP3145935A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15169052.6A EP3095787A1 (fr) 2015-05-22 2015-05-22 Composés pharmaceutiquement actifs en tant qu'inhibiteurs de la dag-lipase
PCT/EP2016/061620 WO2016188972A1 (fr) 2015-05-22 2016-05-23 Composés pharmaceutiquement actifs à titre d'inhibiteurs de lipases dag

Publications (1)

Publication Number Publication Date
EP3145935A1 true EP3145935A1 (fr) 2017-03-29

Family

ID=53274416

Family Applications (2)

Application Number Title Priority Date Filing Date
EP15169052.6A Withdrawn EP3095787A1 (fr) 2015-05-22 2015-05-22 Composés pharmaceutiquement actifs en tant qu'inhibiteurs de la dag-lipase
EP16727341.6A Withdrawn EP3145935A1 (fr) 2015-05-22 2016-05-23 Composés pharmaceutiquement actifs à titre d'inhibiteurs de lipases dag

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP15169052.6A Withdrawn EP3095787A1 (fr) 2015-05-22 2015-05-22 Composés pharmaceutiquement actifs en tant qu'inhibiteurs de la dag-lipase

Country Status (2)

Country Link
EP (2) EP3095787A1 (fr)
WO (1) WO2016188972A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018133818A1 (fr) * 2017-01-19 2018-07-26 江苏恒瑞医药股份有限公司 Procédé de préparation de dérivés de pyrazolone azoïques à substitution bicyclo et intermédiaires de ceux-ci
CN110412161B (zh) * 2019-07-31 2024-07-26 安徽皖仪科技股份有限公司 一种过硫酸钠中微量溴离子的检测系统及检测方法
CN113797202B (zh) * 2020-06-16 2024-06-28 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂在预防和/或治疗动物的病原体感染中的应用
US20250353841A1 (en) * 2022-05-20 2025-11-20 Sarah Elizabeth Huff Heterocyclic compounds for treating huntington's disease
EP4667468A1 (fr) * 2023-02-14 2025-12-24 Shenzhen Zhongge Biological Technology Co., Ltd. Composé pour inhiber nlrp3, procédé de préparation et utilisation
WO2025111409A1 (fr) * 2023-11-21 2025-05-30 Biogen Ma Inc. Composés hétérocycliques de formule (i) destinés à être utilisés dans le traitement de l'amyotrophie spinale par modulation de l'épissage de smn2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1703407A (zh) * 2002-10-08 2005-11-30 斯克里普斯研究学院 脂肪酸酰胺水解酶抑制剂
US8354548B2 (en) * 2010-02-19 2013-01-15 Bristol-Myers Squibb Company Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2016188972A1 *

Also Published As

Publication number Publication date
WO2016188972A1 (fr) 2016-12-01
EP3095787A1 (fr) 2016-11-23

Similar Documents

Publication Publication Date Title
EP3145935A1 (fr) Composés pharmaceutiquement actifs à titre d'inhibiteurs de lipases dag
Wu et al. Novel spiropyrazolone antitumor scaffold with potent activity: design, synthesis and structure–activity relationship
Kalkhambkar et al. Synthesis of novel triheterocyclic thiazoles as anti-inflammatory and analgesic agents
CA2650798C (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
Wang et al. Discovery of novel N-(5-(arylcarbonyl) thiazol-2-yl) amides and N-(5-(arylcarbonyl) thiophen-2-yl) amides as potent RORγt inhibitors
Gorsuch et al. Synthesis of isothiazol-3-one derivatives as inhibitors of histone acetyltransferases (HATs)
WO2024258652A1 (fr) Composés pour l'inhibition covalente de shp2
CA3248823A1 (fr) Inhibiteur de nav1.8 à cycle condensé aromatique et son utilisation
WO2024112611A1 (fr) Modification ciblée de protéines
HK1199731A1 (en) Inhibitor of human immunodeficiency virus replication
EP2220095A1 (fr) Inhibiteurs de la réplication du virus de l'immunodéficience humaine
JP2012513413A (ja) 脂質レベルを減少させるための化合物、組成物および方法
JP7125495B2 (ja) テトラヒドロイソキノリン化合物、その調製方法、そのような化合物を含む医薬組成物およびその使用
EA017449B1 (ru) Производные замещенных 3-фенил-1-(фенилтиенил)пропан-1-онов и 3-фенил-1-(фенилфуранил)пропан-1-онов, их получение и применение
JP2016517879A (ja) ニコチンアミドホスホリボシルトランスフェラーゼの阻害剤、組成物、生成物、およびその使用
KR101051559B1 (ko) Ｉ군 대사친화성 수용체 길항제로서의 치환된 카르복스아미드
Li et al. Discovery of HWL-088: a highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold
Romagnoli et al. Synthesis and biological evaluation of 2-(3′, 4′, 5′-trimethoxybenzoyl)-3-aryl/arylaminobenzo [b] thiophene derivatives as a novel class of antiproliferative agents
KR20240075860A (ko) 히단토인 화합물 및 이의 의학적 용도
Kowalczyk et al. A straightforward access to 3-trifluoromethyl-1H-indazoles via (3+ 2)-cycloaddition of arynes with nitrile imines derived from trifluoroacetonitrile
Li et al. Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold
Xu et al. Substituted 4-oxo-crotonic acid derivatives as a new class of protein kinase B (PknB) inhibitors: synthesis and SAR study
JP2025504791A (ja) ヒドロキシフェニル部分を含む化合物及びその使用
Bermudez et al. Biological Characterization, Mechanistic Investigation and Structure‐Activity Relationships of Chemically Stable TLR2 Antagonists
HUE024870T2 (en) Substituted 2-oxo and 2-thioxo-dihydroquinoline-3-carboxamides as modulators of KCNQ2 / 3

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20161215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HUMMER, JESSICA J.A.

Inventor name: VAN DER STELT, MARCELIS

Inventor name: BAGGELAR, MARC P.

Inventor name: JANSSEN, FREEK J.

Inventor name: VAN BOECKEL, C.A.A. STAN

INTG Intention to grant announced

Effective date: 20170426

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HUMMER, JESSICA J.A.

Inventor name: BAGGELAR, MARC P.

Inventor name: VAN BOECKEL, C.A.A. STAN

Inventor name: VAN DER STELT, MARCELIS

Inventor name: JANSSEN, FREEK J.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170907